Second Line Treatment With Nal-IRI and S1 in Pancreatic Cancer

NCT03986294 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

122

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Pancreatic Cancer

Interventions

DRUG: S1 + Nal-IRI
DRUG: Nal-IRI+Leucovorin+5-FU

Sponsor

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]